[Therapy of acquired hemorrhagic diatheses].
D000925:Anticoagulants / Q000009:adverse effects*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D007611:Aprotinin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D001780:Blood Coagulation Tests; D001803:Blood Transfusion; D003348:Cortisone / Q000627:therapeutic use*; D005340:Fibrinogen / Q000627:therapeutic use; D005342:Fibrinolysis; D006474:Hemorrhagic Disorders; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011693:Purpura / Q000188:drug therapy; D013921:Thrombocytopenia / Q000188:drug therapy*
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D005340:Fibrinogen; D006493:Heparin; D007611:Aprotinin; D003348:Cortisone
Zur Therapie erworbener hämorrhagischer Diathesen.